General MedicationsORALGeneric

GRIFULVIN V

GRISEOFULVIN, MICROCRYSTALLINE

Standard Dose

250MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

Max Dose

Refer to approved labeling

Primary Use

Marketing status: Discontinued

Summary

Approval overview GRIFULVIN V is listed in Drugs@FDA under application 062279 (ANDA).

Marketing status: Discontinued Active ingredient GRISEOFULVIN, MICROCRYSTALLINE Form and strength TABLET;ORAL - 250MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** Sponsor VALEANT LUXEMBOURG Submission history Latest submission status date: 2014-04-22 00:00:00.

Structured Monograph

Clinical summary

Approval overview GRIFULVIN V is listed in Drugs@FDA under application 062279 (ANDA). Marketing status: Discontinued Active ingredient GRISEOFULVIN, MICROCRYSTALLINE Form and strength TABLET;ORAL - 250MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** Sponsor VALEANT LUXEMBOURG Submission history Latest submission status date: 2014-04-22 00:00:00. Submission type: SUPPL.

Monitoring

• Marketing status: Discontinued

Interaction Notes

No interaction notes stored yet.